Holen Sie sich die Stockscreener-App
4.415
1.03%
0.045
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - lincolnjournal.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc.NUVB - PR Newswire
RBC Capital Lifts PT on Nuvation Bio (NUVB) to $13 From $12 – Here’s Why - Insider Monkey
15 Best Penny Stocks to Buy According to Reddit - Insider Monkey
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript - AOL.com
NUVB: IBTROZI leads in ROS1 lung cancer with rapid uptake, superior efficacy, and expanding indications - TradingView
A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss - simplywall.st
NUVB: Ibtrozi leads ROS1 market growth with superior efficacy and expanding first-line adoption - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PayPal Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – PYPL - GlobeNewswire Inc.
Aug Setups: Will Nuvation Bio Inc outperform the market in YEARLayoff News & Daily Profit Focused Screening - baoquankhu1.vn
Nuvation Bio Earnings Call: IBTROZI Surge, Long Runway - The Globe and Mail
Nuvation Bio Faces Weak Start with 18.49% Gap Down Amid Market Concerns - Markets Mojo
Nuvation Bio Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Citigroup Inc. Has $3.42 Million Stake in Nuvation Bio Inc. $NUVB - MarketBeat
Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors - MSN
Nuvation Bio Stock Hits Day Low of $4.16 Amid Price Pressure - Markets Mojo
Nuvation Bio Hits Day High with Strong 8.72% Intraday Surge - Markets Mojo
Q1 EPS Estimates for Nuvation Bio Reduced by HC Wainwright - MarketBeat
10 Best Low Cost Stocks to Buy Under $5 - Insider Monkey
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch - Bitget
NUVB: First-line patient growth, strong efficacy, and robust cash position drive positive outlook - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Q4 2025 Earnings Call Transcript - Insider Monkey
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - marketscreener.com
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out - GlobeNewswire
Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress - Yahoo Finance
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Nuvation Bio Inc. $NUVB is Aisling Capital Management LP's 4th Largest Position - MarketBeat
NUVB-WT Nuvation Bio NYSE down 27% pre-market after Q4: cash runway focus - Meyka
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks - TipRanks
Nuvation Bio (NUVB) Q4 Revenue Surge Tests Bullish Growth Narrative Against Ongoing Losses - simplywall.st
Nuvation Bio (NUVB) awards stock options and RSUs to company officer - Stock Titan
Director Xiangmin Cui awarded 74,813 Nuvation Bio (NUVB) stock options - Stock Titan
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy - The Globe and Mail
Deep Dive Into Nuvation Bio Stock: Analyst Perspectives (7 Ratings) - Benzinga
UBS Group Lowers Nuvation Bio (NYSE:NUVB) Price Target to $7.00 - MarketBeat
Nuvation Bio (NUVB) Analyst Rating Update: UBS Lowers Price Targ - GuruFocus
NUVB Crosses Below Key Moving Average Level - Nasdaq
Nuvation Bio (NYSE:NUVB) Shares Gap DownShould You Sell? - MarketBeat
NUVB: RBC Capital Raises Price Target for Nuvation Bio | NUVB St - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Nuvation Bio (NYSE:NUVB) Stock - MarketBeat
UBS Adjusts Price Target on Nuvation Bio to $7 From $10, Maintains Neutral Rating - marketscreener.com
Nuvation Bio price target raised to $13 from $12 at RBC Capital - TipRanks
RBC Raises Price Target on Nuvation Bio to $13 From $12, Keeps Outperform, Speculative Risk - marketscreener.com
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch By Investing.com - Investing.com UK
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch - Investing.com Nigeria
Nuvation Bio Posts Narrower FY25 Loss, Highlights IBTROZI Launch And Pipeline Progress; Stock Down - Nasdaq
Nuvation Bio Q4 2025 Earnings Call Transcript - MarketBeat
Assessing Nuvation Bio (NUVB) Valuation After SIGMA Phase 3 Safusidenib Expansion And Rising Investor Interest - simplywall.st
Nuvation Bio Q4 Earnings Call Highlights - MarketBeat
Nuvation Bio reports Q4 EPS (11c), consensus (5c) - TipRanks
Earnings call transcript: Nuvation Bio Q4 2025 sees revenue beat, stock dips - Investing.com
Earnings call transcript: Nuvation Bio Q4 2025 sees revenue beat, stock dips By Investing.com - Investing.com South Africa
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):